Avalon Ventures

Investor type Venture Capital
Founders Kevin Kinsella

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 178
Average round size
info
The average size of a deal this fund participated in
$11M
Portfolio companies 92
Rounds per year 4.56
Lead investments 42
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.48
Exits 46
Key employees 4
Stages of investment
Early Stage Venture
Late Stage Venture
Seed

Areas of investment

  • Software
  • Health Care
  • Biotechnology
  • Enterprise Software
  • Advertising
Summary

Avalon Ventures appeared to be the VC, which was created in 1983. The main department of described VC is located in the La Jolla. The venture was found in North America in United States.

The usual cause for the fund is to invest in rounds with 4-5 partakers. Despite the Avalon Ventures, startups are often financed by Union Square Ventures, Y Combinator, Austin Ventures. The meaningful sponsors for the fund in investment in the same round are Sigma Partners, Foundry Group, Austin Ventures. In the next rounds fund is usually obtained by Union Square Ventures, Sigma Partners, Venrock.

The current fund was established by Kevin Kinsella. Besides them, we counted 4 critical employees of this fund in our database.

For fund there is a match between the location of its establishment and the land of its numerous investments - United States. We can highlight the next thriving fund investment areas, such as Cloud Computing, Software. The fund has no exact preference in some founders of portfolio startups. If startup sums 5+ of the founder, the chance for it to be financed is low. Besides, a startup needs to be aged 2-3 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Zynga, BioVex, Empyr.

Comparing to the other companies, this Avalon Ventures performs on 6 percentage points less the average number of lead investments. The top amount of exits for fund were in 2014. The high activity for fund was in 2014. Despite it in 2019 the fund had an activity. The average startup value when the investment from Avalon Ventures is 50-100 millions dollars. The fund is generally included in 7-12 deals every year. Considering the real fund results, this VC is 12 percentage points more often commits exit comparing to other organizations. The common things for fund are deals in the range of 10 - 50 millions dollars.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Avalon Ventures:
Typical Co-investors
Avalon Ventures is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Avalon Ventures:

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Jnana

Biotechnology
Health Care
Therapeutics
$50M18 Aug 2021 Boston, Massachusetts, United States

Primer

Artificial Intelligence
Content
Machine Learning
$110M22 Jun 2021 San Francisco, California, United States

Janux Therapeutics

Biotechnology
Health Diagnostics
Pharmaceutical
Therapeutics
$125M20 Apr 2021 La Jolla, California, United States

Fortis Therapeutics

Biotechnology
Therapeutics
$40M29 Mar 2021 San Diego, California, United States

Janux Therapeutics

Biotechnology
Health Diagnostics
Pharmaceutical
Therapeutics
$56M03 Mar 2021 La Jolla, California, United States

Pando

Career Planning
Enterprise Software
Health Care
Logistics
Management Information Systems
mHealth
Personal Finance
Pharmaceutical
Sports
Supply Chain Management
$8M09 Jun 2020 Palo Alto, California, United States

Figg

Advertising
Financial Services
Information Technology
Marketing
Marketplace
22 Apr 2020 Saint Paul, Minnesota, United States

AristaMD

Business/Productivity Software
Consulting Services (B2B)
Health Care
Hospital
Managed Care
mHealth
Other Healthcare Technology Systems
Software
$18M31 Mar 2020 San Diego, California, United States

Simulmedia

Ad Targeting
Advertising
Impact Investing
Marketing
$29M12 Jun 2019 New York, New York, United States
News
Jnana Therapeutics Closes $50 Million Series B Financing to Advance Lead PKU Program and Small Molecule Pipeline Based on Next Gen Chemoproteomic Platform

– Jnana Therapeutics, a biotechnology company utilizing its next generation chemoproteomic platform to target SLC transporters and other well-validated but hard-to-drug targets, announced the closing of a $50m Series B financing.
– The financing was led by RA Capital Management, and included all existing investors, including Polaris Partners, Versant Ventures, Avalon Ventures, AbbVie Ventures and Pfizer Ventures.
– Proceeds from this financing will enable Jnana to progress its lead program for the treatment of phenylketonuria (PKU) into clinical development, while advancing a pipeline of additional programs and continuing to invest in its innovative and validated RAPID platform for the discovery of small molecule therapeutics for hard-to-drug targets.

Fortis Therapeutics Raises $40M in Series A Funding

– Fortis Therapeutics from San Diego is developing novel antibody-drug conjugate FOR46 for late-stage multiple myeloma and metastatic castration-resistant prostate cancer.
– The company closed a $40m Series A financing cofunded by Avalon Ventures, Bregua Corporation, Lilly Asia Ventures, Osage University Partners, Vivo Capital, the Myeloma Investment Fund, the venture philanthropy fund of the Multiple Myeloma Research Foundation (MMRF), and Fulcrum 2020, LLC.
– The new investment will be used to advance FOR46 in clinical trials for the treatment of relapsed or refractory multiple myeloma and metastatic castration-resistant prostate cancer.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Avalon Ventures?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: